The packet's definition attributes the condition to the presence of Lewy bodies, which are protein deposits, in the midbrain and cerebral cortex, together with loss of cholinergic and dopaminergic neurons. The packet lists two genes, SNCA (on chromosome 4) and SNCB (on chromosome 5), and an autosomal dominant inheritance pattern. ClinGen validity classifications for these genes are not supplied in the packet, and the packet does not specify which individuals or families the gene and inheritance entries apply to.

Diagnostic methods, criteria, and testing approaches are not certified in this packet.

The packet's approved treatment record lists DATSCAN (generic name ioflupane I-123), with an NDA approval type, FDA center CDER, an approval date of 2011-01-14, and an active market status. The packet does not state the indication for this record, so its relationship to Lewy body dementia is not specified here. Foundational therapies and management guidance are not certified in this packet.

Prognosis is not certified in this packet.

ClinicalTrials.gov records in this packet show an active research area for Lewy body dementia, with a mixed sponsor profile. Intervention types across the listed trials include drug therapy, medical devices, procedural interventions, and other interventions, and top sponsors listed include AC Immune SA, ACADIA Pharmaceuticals Inc., and Aptinyx. Records that name Lewy body disease or Lewy body dementia include NCT05014971, Telehealth in Lewy Body Dementia, sponsored by the University of Florida and listed as active, not recruiting, and NCT06846658, a study of early biomarkers in Parkinson disease, atypical parkinsonisms, and neurocognitive disorders due to Lewy body disease, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Other listed records address dementia, cognitive decline, or neurodegenerative disease more broadly, and trial titles do not establish the effect of any intervention on Lewy body dementia. The research landscape digest classifies the publication literature as predominantly basic science and preclinical, with biomarker and gene therapy publications present. Active clinical trials for this condition are listed on ClinicalTrials.gov.